The clinical trials industry continues to face new and unprecedented challenges. Trust in the clinical trials enterprise has suffered from media coverage of unanticipated safety findings, an apparent lack of transparency and a drug development environment rife with multiple conflicts of interest. The ethical viewpoint has become increasingly important, especially in this age of radical advances in medicine and technology. Here is an article that discuss academic freedom in clinical research.
from David G. Nathan and David J. Weatherall “Academic Freedom in Clinical Research”. New England Journal of Medicine (October 24, 2002), Volume 347:1368-1371.